CCR5 and gastric cancer: Moreover, treatment with 5-AZA, a potent DNMT1 inhibitor, or with the CCR5-antagonist MVC slowed GC tumor xenograft growth, revealing the antitumor effects of DNMT1 suppression by the inhibition of CCR5 engagement in GC.